<h2 dir="ltr">Chronic Pruritus</h2>
Chronic Pruritus is persistent itching lasting over six weeks, often linked to skin, systemic, or nerve-related conditions. It impacts quality of life and requires targeted treatment based on the underlying cause.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total Prevalent Cases&nbsp;
</li>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalent Cases&nbsp;
</li>
<li dir="ltr" aria-level="1">
Gender-Specific Diagnosed Prevalent Cases&nbsp;
</li>
<li dir="ltr" aria-level="1">
Age-Specific Diagnosed Prevalent Cases&nbsp;
</li>
<li dir="ltr" aria-level="1">
Severity-Specific Diagnosed Prevalent Cases
</li>
<li dir="ltr" aria-level="1">
Etiology-Specific Diagnosed Prevalent Cases&nbsp;
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/chronic-pruritus-epidemiology-forecast">Chronic Pruritus Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, there were ~98 million prevalent and ~22 million diagnosed chronic pruritus cases in the 7MM, expected to grow at a 3.3% CAGR by 2034.
</li>
<li dir="ltr" aria-level="1">
The US had ~9M diagnosed cases, the highest in the 7MM.
</li>
<li dir="ltr" aria-level="1">
Germany led EU4 &amp; the UK with ~3M cases; Spain had the lowest (~1M).
</li>
<li dir="ltr" aria-level="1">
Japan recorded ~4M cases in 2024.
</li>
<li dir="ltr" aria-level="1">
France reported ~730K male and ~900K female cases.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/chronic-pruritus-market">Chronic Pruritus Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the chronic pruritus market in the 7MM was valued at USD 3.5 billion and is expected to grow through 2034.
</li>
<li dir="ltr" aria-level="1">
The US led with USD 1.8 billion, driven by upcoming therapies.
</li>
<li dir="ltr" aria-level="1">
EU4 &amp; the UK contributed USD 1.2 billion (36% of the total), projected to rise.
</li>
<li dir="ltr" aria-level="1">
Germany topped EU4 &amp; the UK with ~USD 430 million, followed by Italy (~USD 240 million) and France (~USD 210 million).
</li>
</ul>
<h3 dir="ltr">Chronic Pruritus Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
The increasing incidence of dermatological and systemic diseases such as atopic dermatitis, chronic kidney disease, liver disorders, and neuropathic conditions is driving demand for chronic pruritus treatment options.
</li>
<li dir="ltr" aria-level="1">
Growing R&amp;D in neuroimmune-targeted therapies, JAK inhibitors, and biologics is expanding treatment possibilities, improving efficacy, and drawing investment into this under-addressed segment.
</li>
</ul>
<h3 dir="ltr">Chronic Pruritus Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Chronic pruritus often stems from diverse and overlapping etiologies, making accurate diagnosis challenging. Many patients go undiagnosed or untreated, limiting treatment uptake.
</li>
<li dir="ltr" aria-level="1">
Most current treatments rely on off-label use of antihistamines, antidepressants, or immunosuppressants, highlighting the lack of specific approved therapies, which slows market penetration and physician confidence.
</li>
</ul>
<h3 dir="ltr">Chronic Pruritus Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
DUPIXENT
</li>
<li dir="ltr" aria-level="1">
Linerixibat (GSK2330672)
</li>
<li dir="ltr" aria-level="1">
NEMLUVIO/MITCHGA
</li>
<li dir="ltr" aria-level="1">
Volixibat
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr">Chronic Pruritus Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Sanofi
</li>
<li dir="ltr" aria-level="1">
Regeneron
</li>
<li dir="ltr" aria-level="1">
GlaxoSmithKline
</li>
<li dir="ltr" aria-level="1">
Galderma
</li>
<li dir="ltr" aria-level="1">
Chugai Pharmaceutical
</li>
<li dir="ltr" aria-level="1">
Mirum Pharmaceuticals
</li>
</ul>
And others.

Chronic Pruritus Market

Chronic Pruritus Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape